Analysts See $0.18 EPS for Caesarstone Ltd. (CSTE); Lexicon Pharmaceuticals, Inc. (LXRX) Had 4 Bulls

April 24, 2018 - By Dolores Ford

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Logo

Analysts expect Caesarstone Ltd. (NASDAQ:CSTE) to report $0.18 EPS on May, 9.They anticipate $0.13 EPS change or 41.94% from last quarter’s $0.31 EPS. CSTE’s profit would be $6.18 million giving it 26.04 P/E if the $0.18 EPS is correct. After having $0.19 EPS previously, Caesarstone Ltd.’s analysts see -5.26% EPS growth. The stock decreased 1.32% or $0.25 during the last trading session, reaching $18.75. About 75,464 shares traded. Caesarstone Ltd. (NASDAQ:CSTE) has declined 45.24% since April 24, 2017 and is downtrending. It has underperformed by 56.79% the S&P500.

Among 9 analysts covering Lexicon Pharmaceuticals (NASDAQ:LXRX), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Lexicon Pharmaceuticals had 21 analyst reports since August 4, 2015 according to SRatingsIntel. The stock has “Buy” rating by Wedbush on Thursday, November 30. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, September 8. The stock has “Buy” rating by Citigroup on Tuesday, August 2. The firm has “Buy” rating given on Friday, October 7 by H.C. Wainwright. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has “Outperform” rating given on Friday, August 5 by Wedbush. The rating was maintained by Wedbush on Monday, August 7 with “Buy”. Gabelli upgraded the shares of LXRX in report on Monday, September 28 to “Hold” rating. The company was downgraded on Wednesday, February 14 by JP Morgan. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has “Overweight” rating given on Monday, August 10 by JP Morgan. The firm has “Buy” rating by Wedbush given on Monday, March 12. See Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) latest ratings:

16/04/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $38 New Target: $40 Maintain
12/03/2018 Broker: Wedbush Rating: Buy New Target: $38.0 Maintain
23/02/2018 Broker: Needham Rating: Hold Downgrade
14/02/2018 Broker: J.P. Morgan Rating: Sell New Target: $10.0 Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
30/11/2017 Broker: Wedbush Rating: Buy New Target: $38.0 Maintain

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company has market cap of $857.41 million. The firm offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. It currently has negative earnings. The Company’s orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain.

The stock decreased 1.58% or $0.13 during the last trading session, reaching $8.12. About 178,405 shares traded. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has declined 43.19% since April 24, 2017 and is downtrending. It has underperformed by 54.74% the S&P500.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: